Emerging Drug Developers
Commercialising new therapies
Building commercial-scale manufacturing capability for the first time — with a partner who has navigated the full journey from process development to GMP production.
Bridge Health is powered by continuous manufacturing expertise that enables our partners to make API manufacturing a reality.
The way the world manufactures medicines is inefficient, costly, and slow. The consequences reach far beyond operations — it determines what treatments exist, what they cost, and who controls access to them.
If you are a pharmaceutical manufacturer or an emerging drug company, you know that relying on batch manufacturing is holding you back.
The question is what you're going to do about it.
Across the global pharmaceutical industry, every year.
Source: Nickerson & Macher, Washington University · GeorgetownAcross the global pharmaceutical industry, every year.
12 months from API to market is standard for batch. Continuous manufacturing has demonstrated the same in ~10 days.
Source: FDA · ICH Q13 implementation studies12 months from API to market is standard for batch. Continuous manufacturing has demonstrated the same in ~10 days.
Most countries cannot independently manufacture the active ingredients required for their essential medicines. Production is concentrated in China and India.
Most countries cannot independently manufacture the active ingredients required for their essential medicines. Production is concentrated in China and India.
The single biggest cost lever for generics manufacturers — and the most underutilised.
Source: BCG, Generic Drug COGS AnalysisThe single biggest cost lever for generics manufacturers — and the most underutilised.
The science of continuous manufacturing is proven. The regulatory pathway is open. What most organizations still need is a partner with hands on experience.
View regulatory resources →ICH Q13 was adopted globally in 2023. The FDA's FRAME initiative has designated end-to-end continuous manufacturing its first priority technology. The AMT Designation Program granted its first designation in April 2025.
We are world-leading experts in continuous manufacturing with experience in development, scale up and industrial production.
Our founding team developed a continuous-flow process for artemisinin, the world's primary malaria treatment — at one of the world's leading research institutions, the Max Planck Institute. In 2021, the American Chemical Society awarded the team the Science Prize for Affordable Green Chemistry.
Bridge Health then springboarded this research into continuous manufacturing enabled commercial scale production, to meet >25% global unmet demand for artemisinin.
That's the foundation we bring to every engagement.
Learn more about our expertise →Continuous manufacturing transitions don't fail at the science. They fail at implementation: when decisions are made in the wrong order, workstreams run without coordination, or regulatory strategy gets tacked on after the engineering is already done. We work across every phase of your programme so each decision is made with the next one in mind.
Building commercial-scale manufacturing capability for the first time — with a partner who has navigated the full journey from process development to GMP production.
Adopting continuous manufacturing to reduce costs, improve supply resilience, and build a lasting competitive advantage — with the capability staying in-house.
Turning healthcare sovereignty from policy commitment into operational manufacturing reality — with structured knowledge transfer that builds capability that lasts.
We work with a focused number of clients at any one time. If continuous manufacturing is on your agenda — at any stage — we'd like to hear from you.